The Boao Lecheng International Medical Tourism Pilot Zone in Hainan was officially established with the approval of the State Council on February 28, 2013. It was granted nine preferential policies to pilot the development of international medical tourism-related industries such as licensed medical services, health management, rehabilitation and elderly care, and medical aesthetics. The Pilot Zone aims to gather high-end international and domestic medical tourism services and cutting-edge global medical and pharmaceutical achievements, building an international hub for medical technology services.
An up-to-date List of Approved Stem Cell & Gene Therapies in Regenerative Medicine
Discover all approved stem cell and gene therapies at the Pilot Zone, China’s premier medical tourism destination. From ¥16,000 to ¥480,000, treatments cover osteoarthritis, COPD, heart failure, and rare diseases. Explore five batches of cutting-edge regenerative medicine with transparent pricing and world-class hospitals. The list only covers the regenerative medicine applications of stem cell and gene therapies. There are multiple cancer immunotherapies have been approved within the Pilot Zone but these are out of the scope of this website.
| # | Indications | Stage of Indication | Therapy | Cost (RMB) | Year of Approval | |
|---|---|---|---|---|---|---|
| 1 | Knee Osteoarthritis | • Kellgren-Lawrence Grade II-IV knee osteoarthritis • Cartilage defects, joint inflammation • Failed conservative treatment ≥3 months | Umbilical Cord MSC | ¥36,000/cycle (Single knee) | Mar. 2025 | |
| 2 | COPD | • Moderate-to-severe chronic obstructive pulmonary disease (GOLD Grade II-IV) • Pulmonary fibrosis, alveolar structure damage • Chronic respiratory failure | Airway Basal Stem Cells | ¥150,000/cycle | Mar. 2025 | |
| 3 | Heart Failure | • Chronic heart failure with LVEF ≤40% • NYHA Class II-IV • Ischemic or dilated cardiomyopathy • On stable optimal medical therapy | Umbilical Cord MSC | ¥60,000/cycle (3 cycles recommended) | Mar. 2025 | |
| 4 | GvHD | • Acute or chronic graft-versus-host disease post-HSCT • Steroid-resistant or steroid-dependent • No HLA matching required | MSC | ¥80,000/cycle (1 vial/dose) | Apr. of 2025 | |
| 5 | ILD | • Interstitial lung disease (pulmonary fibrosis, alveolitis) • Idiopathic pulmonary fibrosis (IPF) • DLCO 30-80% predicted • Failed anti-fibrotic drug therapy | Airway Basal Stem Cells | ¥150,000/course | Apr. 2025 | |
| 6 | Bronchiectasis | • Bronchiectasis with airway structure destruction • Recurrent infections • Chronic cough with sputum production • Failed conventional antibiotic therapy | Airway Basal Stem Cells | ¥150,000/course | Apr. 2025 | |
| 7 | Retinal Dystrophy | • RPE65 biallelic mutation-associated inherited retinal dystrophy • Leber congenital amaurosis • Vision loss in childhood • Confirmed genetic diagnosis | RPE65 Gene Therapy | ¥480,000/eye | Apr. 2025 | |
| 8 | Pulmonary Fibrosis | • Idiopathic pulmonary fibrosis (IPF) • Connective tissue disease-associated ILD • Chronic hypoxemia • Failed pirfenidone/nintedanib therapy | Menstrual Blood-derived MSC | ¥140,000/course | Apr. 2025 | |
| 9 | POI | • Premature ovarian insufficiency (POI) • Age <40 years with menstrual abnormalities • Decreased ovarian reserve (AMH <1.1) • Fertility preservation or restoration | Umbilical Cord MSC | ¥80,000/cycle | Aug. 2025 | |
| 10 | Rheumatoid Arthritis | • Moderate-to-severe rheumatoid arthritis • DAS28 >3.2 • Failed ≥2 DMARDs including methotrexate • Disease duration ≥6 months • No severe joint deformity (Stage IV) | Umbilical Cord MSC | ¥50,000/cycle | Nov. 2025 | |
| 11 | Liver Cirrhosis | • Decompensated liver cirrhosis • Child-Pugh Class B or C • MELD score 10-20 • No hepatocellular carcinoma • No severe portal hypertension complications | Umbilical Cord MSC (VUM02) | ¥150,000/cycle | Nov. 2025 | |
| 12 | Periodontal Disease | • Moderate-to-severe periodontitis • Periodontal bone defects • Gum recession • Failed conventional periodontal treatment • Tooth mobility Grade I-II | Dental Pulp MSC | ¥59,800/tooth | Nov. 2025 | |
| 13 | Decompensated Liver Cirrhosis | • Decompensated liver cirrhosis • Ascites, variceal bleeding history • Hepatic encephalopathy episodes • Alternative to liver transplantation • No active alcohol abuse | Menstrual Blood MSC | ¥150,000/course | Mar. 2026 | |
| 14 | Type 2 Diabetes | • Type 2 diabetes mellitus • HbA1c >7.5% despite 3 oral hypoglycemic agents • Disease duration 5-15 years • C-peptide >0.3ng/mL • No severe diabetic complications | Umbilical Cord MSC | ¥58,000/injection (3 injections/course) | Mar. 2026 |